Latest Breaking News On - Iainb mcinnes - Page 1 : vimarsana.com

Early Guselkumab PsA Response Linked to Long-Term Quality of Life Improvement

Post-hoc analysis from DISCOVER-2 show patients who achieve a clinical response by week 8 generally go on to see quality-of-life improvements past 1 year.

Hot Topics in Immune-Mediated Inflammatory Diseases: Highlights from AWIR 2022

Better use of cytokine signalizing could 'revolutionize' rheumatology treatment

Correctly identifying cytokine pathways that are dysregulated in any given rheumatology patient could lead to better use of current biologic therapies, said a presenter at the 2022 Association of Women in Rheumatology annual conference.

EULAR's Consultation Service expanded to address a more extensive range of research needs

JAK Inhibitor Promising in Psoriatic Arthritis

email article The oral JAK inhibitor upadacitinib (Rinvoq), approved for use in rheumatoid arthritis, also showed promise for psoriatic arthritis in a phase III trial comparing the drug with placebo and adalimumab (Humira). At week 12, 20% improvements on the criteria of the American College of Rheumatology (ACR20) were seen in 70.6% of patients receiving 15 mg daily of upadacitinib; 78.5% of those given 30 mg per day; 65% of those receiving subcutaneous adalimumab, 40 mg every other week; and 36.2% of those assigned to placebo, reported Iain B. McInnes, MD, PhD, of the University of Glasgow in Scotland, and colleagues. Both upadacitinib doses were noninferior to adalimumab on the ACR20 criteria, and the 30 mg dose was superior, the investigators reported in the study online in the